Home Compliance Will FDA and DOJ Reassert Their Enforcement Muscle With Life Sciences in... ComplianceExpert OpinionFCANews Will FDA and DOJ Reassert Their Enforcement Muscle With Life Sciences in 2022? January 25, 2022 29 Share FacebookLinkedinTwitter grandbrothers | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Compliance Defense Contractor Pleads Guilty to Bribery Conspiracy Worth More Than $100 Million Compliance CFIUS Update: Larger Penalties, Sharper Monitoring Compliance Who Needs FEPA?